ARTICLE | Company News
argenx gets first milestone payment from AbbVie for immuno-oncology therapy
March 22, 2019 5:27 PM UTC
AbbVie started a Phase I trial of ABBV-151 to treat solid tumors, triggering a $30 million milestone payment to argenx...
BCIQ Target Profiles